Showing results (1-10 of 377) with videos related to

Sort By:
Pageof 38
Archives D'Anatomie Et De Cytologie Pathologiques|January 1, 1995
[Mesenchymal breast sarcomas: general review]M Spielmann, L Zelek, A Llombart
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancerM Spielmann, A Llombart, L Zelek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-upL Zelek, A Llombart-Cussac, P Terrier, et al.
Studies in Health Technology and Informatics|October 18, 2001
A before-after study using OncoDoc, a guideline-based decision support-system on breast cancer management: impact upon physician prescribing behaviourJ Bouaud, B Séroussi, E C Antoine, et al.
Bulletin Du Cancer|February 1, 1997
[Angiosarcoma of the breast. Apropos of 8 cases and review of the literature]J L Molitor, A Llombart, J M Guinebretière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanesL Zelek, S Barthier, M Riofrio, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|December 29, 2005
[Chemotherapy in soft tissue sarcomas]L Zelek
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2005
Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'G Freyer, A-C Braud, P Chaibi, et al.
Cancer|December 18, 2001
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinomaL Zelek, S Barthier, M Riofrio, et al.
British Journal of Cancer|June 1, 2006
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerL Zelek, A Yovine, E Brain, et al.
Pageof 38